Volume 10, Issue 8

PrEP: The Newest Chapter

In this issue:

The long-awaited approval of a second long-acting injectable PrEP formulation — twice-yearly lenacapavir — has come. What are the most important things clinicians need to understand when considering prescribing this new agent?  

How does Q6 months LA lenacapavir differ from already available LA cabotegravir? Which patients is appropriate for? What kinds of monitoring are required, both at treatment initiation and with every following injection? What are the predominant safety issues, and how should they be managed?   

Join us as Matthew Spinelli, MD, MAS, Associate Professor of HIV, Infectious Disease, and Global Medicine at Zuckerberg San Francisco General Hospital, shares his experience and expertise in helping clinicians considering either of these LA PrEP options … in this issue of eHIV Review.  

Learning objective:

Assess the efficacy, safety, and potential indications for new and emerging PrEP options 

Author:

Matthew Spinelli, MD, MAS
Matthew Spinelli, MD, MAS

Associate Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, CA
(he/him/his)

Program Directors:

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Matthew Spinelli, MD, MAS

Associate Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, CA
(he/him/his)

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: February 19, 2026
Expiration date: February 18, 2028